The SLCO1B1 c.521T>C RealFast™ Assay is the easy way to determine the response to statin therapy and thus avoid dose-dependent adverse events. Statins (e.g. Simvastatin) are most widely prescribed as treatment for low-density lipoprotein cholesterol reduction and control. In general statins are considered as safe and well tolerated drugs. However, some patients experience severe side effects and opt to discontinue therapy. The clinical spectrum may range from frequent pain with or without evidence of muscle degradation to a very rare but severe muscle damage with acute kidney injury (rhabdomyolysis). Patients carrying the SLCO1B1 c.521C allele have a higher risk of simvastatin induced myopathy and rhabdomyolysis. The Clinical Pharmacogenetic Implementation Consortium (CPIC) highly recommends to adjust simvastatin dose according to the SLCO1B1 c.521T>C genotype. SLCO1B1 PCR SLCO1B1 PCR
The SLCO1B1 gene codes for the solute carrier organic anion transporter family member 1B1 protein and affects the uptake and metabolism of statins in the liver. The risk for simvastatin-related myopathy is dose-dependent and 4 times higher in patients carrying one c.521T>C allele and 17 times higher in homozygous patients (CC).
|SLCO1B1 c.521T>C RealFast™ Assay||7-210||100 reactions||Detects a variant in SLCO1B1 gene in patients who are at higher risk for developing statin-induced myopathy|
|SLCO1B1 c.521T>C RealFast™ Assay||7-213||32 reactions||Detects a variant in SLCO1B1 gene in patients who are at higher risk for developing statin-induced myopathy|